Phase 2 N=22 Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Complete Response Rate to Induction Therapy — 64 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=59 Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Phase 2 N=30 Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Overall Response Rate (ORR) at the Completion of Induction Chemotherapy, Which is the Percent of Complete Responses (CR) Plus Percent of Partial Responses (PR). — 90…
Phase 2 N=39 Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14
Phase 2 N=38 Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Overall Response Rate — 92 percentage of patients
Phase 2 N=68 S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Lymphoma
Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…
Phase 2 N=56 S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma
Lymphoma
Primary: Progression-free Survival — 90 percentage of participants
Phase 3 N=503 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Phase 2 N=43 Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
Lymphoma
Primary: Rate of Immunological Response to Vaccination — 0; 15 participants
Phase 2 N=26 Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
Mantle Cell Lymphoma · Lymphoma, Mantle Cell
Primary: Median Progression-free Survival (PFS) in Participants Treated With Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (EPOCH-R) — 23.5…
Phase 2 N=77 Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
Contiguous Stage II Mantle Cell Lymphoma · Noncontiguous Stage II Mantle Cell Lymphoma · Stage I Mantle Cell Lymphoma
Primary: Complete Response (CR) Rate — 0.68 proportion
Phase 2 N=48 A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Mantle Cell Lymphoma
Primary: Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR) — 19; 8 participants
Phase 2 N=76 Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL
Non-Hodgkin's Lymphoma
Primary: ORR — 88; 81 percentage of patients
Phase 2 N=22 R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
Lymphoma
Primary: Progression-free Survival Rate — 91; 78; 69 percentage of participants
Phase 2 N=25 Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Mantle-Cell Lymphoma
Primary: Progression-Free Survival (PFS) — 8 years
Phase 2 N=16 Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Primary: Objective Response Rate (CR + PR) — 46.7 percentage of participants
Phase 2 N=53 EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
Lymphoma, Mantle Cell · Mantle Cell Lymphoma
Primary: Progression Free Survival (PFS) — 27.2; 33.5; 7.8 Months
Phase 2 N=24 Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
Lymphoma · Mantle Cell Lymphoma · Indolent Lymphoma
Primary: Progression-free Survival at 2 Years — 15 Participants
Phase 2 N=37 Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Stage I Mantle Cell Lymphoma · Stage II Contiguous Mantle Cell Lymphoma · Stage II Non-Contiguous Mantle Cell Lymphoma
Primary: Proportion of Patients Experiencing a Complete Response — .62 Proportion of participants
Phase 2 N=14 Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg
Phase 2 N=43 A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Mantle-Cell Lymphoma
Primary: Phase I: Dose Limiting Toxicities (DLT) Rate — 3; 5; 0; 1 Participants
Phase 2 N=53 S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
Lymphoma
Primary: Progression-Free Survival (PFS) at 2 Years — 82; 81 percentage of participants
Phase 2 N=23 Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
Contiguous Stage II Mantle Cell Lymphoma · Noncontiguous Stage II Mantle Cell Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Two-year Disease-free Survival — 90 percentage of participants
Phase 2 N=53 Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants
Phase 2 N=11 Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma
Untreated Mantle Cell Lymphoma
Primary: Number of Participants With Toxicity — 8 participants
Phase 2 N=56 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Phase 2 N=28 Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
Lymphoma
Primary: Number of Participants With Adverse Events (e.g. Toxicity) — 28 Participants
Phase 2 N=49 Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma · Untreated
Primary: 3-year Progression-free Survival (PFS) — 63 % of pts progression-free survival
Phase 2 N=33 Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
Mantle Cell Lymphoma
Primary: Complete Response (CR) Rate at End of Induction — 28; 4; 0; 0 Participants
N/A N=36 Non-Myeloablative Allogeneic Stem Cell Transplantation
Lymphoma
Primary: Overall Survival at 100 Days Post Transplant (Number of Surviving Participants) — 16; 19 participants